Objectives: While systemic corticosteroids (SCS) are widely used to prevent relapse in adults with acute asthma discharged from the emergency department, the most effective route of administration is unclear. The objective of this review was to examine the effectiveness of SCS in adults and to identify the most effective route of SCS to preventing relapse.
short-course corticosteroids and placebo were not statistically significantly different (OR = 0.37; 95% CrI = 0.04 to 3.38). PB analysis favored IM corticosteroids (62%) followed by PO short-course (20.3%) and PO long-course (14.1%) corticosteroids.
Conclusions:
The network analysis identified IM corticosteroids and PO long-course corticosteroids as the most effective strategies to prevent relapse among adults with acute asthma, compared to PO short-course corticosteroids. The lack of significant findings with PO short-course corticosteroids is likely due to the paucity of research. Further comparative studies are required to determine the safety and effectiveness of briefer PO SCS treatment options in adults.
A cute asthma remains a common cause of adult presentations to the emergency department (ED). 1 While the majority of adults with acute asthma can be safely discharged from the ED, approximately 17%-18% of adults will relapse. 2, 3 Systemic corticosteroids (SCS) are the cornerstone of treatment following discharge from most international locations; however, variation in the dose, treatment duration, and agent exists. 4 In Canadian 5 and U.S. 2 studies SCS treatment is predominantly long course (≥7 days) and fixed dose and prednisone is the commonest treatment agent.
While high-quality systematic review evidence exists demonstrating the effectiveness of SCS (intramuscular [IM] and oral [PO] corticosteroids) in reducing relapse, 6 the effectiveness of the various delivery routes of administering SCS to prevent relapse in adults is unclear. A previous umbrella review reported similar relapse rates between short versus long course of PO corticosteroids, as well as IM versus PO corticosteroids. 7 The search in the umbrella review was limited to four databases, and an updated examination of the literature is required before any recommendations regarding the optimal route of SCS to reduce relapse in adults with acute asthma can be made.
The objective of this systematic review is to assess the effectiveness of SCS to reduce the risk of relapse in adults with acute asthma discharged from the ED or other acute care setting and explore the optimal route of SCS administration. First, a meta-analysis was conducted to investigate a direct comparison between studies comparing SCS to placebo in adults, as the previous Cochrane review 6 examined the effectiveness of SCS in a combined adult and pediatric patient population. Then, to identify the most effectiveness route of administering SCS to reduce relapse, a Bayesian network analysis was conducted to allow for indirect comparisons of the differing routes of SCS administration to placebo. It was hypothesized that SCS would be effective in mitigating relapse in adults, with longcourse corticosteroids being identified as the most effective route of administration.
METHODS

Protocol
A study protocol was developed a priori to define the objectives, search strategy, selection criteria, primary outcome, data collection, and define the analysis. A meta-analysis was conducted after the initiation of the review to conduct a direct comparison of SCS versus placebo to reduce relapse. This review followed the PRISMA guidelines of outcome reporting. 8 
Inclusion/Exclusion
Randomized controlled trials or prospective controlled clinical trials comparing the effectiveness of SCS (IM, oral short-course [PO sc ], oral long-course [PO lc ] corticosteroids) to placebo or other SCS regimens in adults presenting to an acute care setting (e.g., ED, urgent care clinic) with acute asthma were included. Patients could receive either a single dose of IM corticosteroids or a short (1-6 days) or long (7-10 days) course of PO corticosteroids prior to discharge. Eligible trials were permitted to employ fixed or tapered regimens for the PO corticosteroids. Ineligible studies included those assessing only the palatability of PO SCS, studies comparing tapered versus fixed dose of PO SCS, or comparing SCS to either inhaled (ICS) or intravenous (IV) corticosteroids. Studies assessing hospitalized patients were not eligible, as the objective of this review was to examine relapse following discharge from an acute care setting
Outcome
The primary outcome of this review was to examine the effectiveness of SCS to reduce relapse among adults with acute relapse and to identify the routes of administering SCS that are the most effective in mitigating relapse. While the effectiveness of SCS was established previously in a Cochrane review, 6 the meta-analysis included both adult and pediatric patients, and as such, this review attempted to examine the effectiveness of SCS versus placebo among adult patients only. An "asreported" analysis was completed. To examine the most effective route of administration, the effectiveness of the various routes of SCS to mitigate relapse within 10 days and greater than 10 days postdischarge was examined. As-reported and intention-to-treat (ITT) analyses on relapse were performed. Relapse events, as reported in the text of the articles, were considered for the as-reported analysis. For ITT analysis, it was assumed that a similar proportion of patients lost to follow-up relapsed as those patients included in the analysis. For a conservative estimate of relapse, the estimated relapse rate among the patients lost to follow-up were doubled and combined with the as-reported relapse events. Patients excluded due to protocol violations, such as patients excluded from the study due to admission prior to discharge from the ED, age violations, or vomiting the medications in the ED prior to discharge, were not considered as lost to follow-up. Relapse to additional care included return to the ED/acute care, in addition to requiring additional corticosteroids or hospitalizations following discharge.
Search Methods for Identification of Studies
A systematic search developed by a health librarian (SC) was conducted of nine electronic databases using both controlled vocabulary and natural language terms and a variety of specific and general terms for corticosteroids, which were modified for each database (see Data Supplement S1, available as supporting information in the online version of record of this paper, which is available at http://onlinelibrary.wiley.com/ doi/10.1111/acem.13107/full). The search included literature from 1946 to September 2015. The initial search was conducted in June 2012 and all of the databases, except for international pharmaceutical abstracts were updated in September 2015. Additionally, the Cochrane Airways Group provided search results from the Airways Group Specialised Register from 2002 to 2015. No studies were excluded on the basis of language or year of publication. Foreign language articles were translated by a native speaker or Google Translate 9 if a native speaker was not available.
The gray literature was searched for additional citations via clinical trial registries and Google Scholar, and bibliographies from included studies and reviews were searched for any additional citations. A SCOPUS forward search of a sentinel paper 10 Data Collection and Analysis Selection of Studies. Two of three independent reviewers (EC, SWK, TYA) identified potentially relevant studies via abstracts and titles. Once identified and using predefined criteria, at least two of the three independent reviewers (EC, SWK, TYA) assessed the full text of the articles for eligibility. Disagreements were resolved and discussed by third party adjudication (CVR or BHR) until a consensus was reached.
Assessment of Risk of Bias. Risk of bias assessment of included studies was completed with the Cochrane risk of bias assessment tool 11 by at least two independent reviewers (EC, SWK, TYA). The tool explores several sources of potential bias in the conduct of randomized or controlled clinical trials including: 1) sequence generation (randomization), 2) allocation concealment, 3) blinding of participants and personnel, 4) blinding of outcome assessors, 5) incomplete outcome reporting, 6) selective reporting, and 7) other sources of potential bias. Disagreements were resolved and discussed by third party adjudication (CVR or BHR) until a consensus was reached.
Data Extraction. Data were extracted by at least two independent reviewers (EC, SWK, TYA) and checked for reliability (SWK). Any discrepancies were discussed and disagreements were resolved via thirdparty adjudication (BHR). Extracted data included information on study population, study design, cointerventions, interventions, and outcomes. Primary authors were contacted for clarification if needed.
Data Synthesis. Studies comparing SCS versus placebo to reduce relapse were compared in Review Manager (RevMan; Version 5.3). Pooled dichotomous variables were calculated as risk ratios (RR) with 95% confidence intervals (CI) using a random-effects model and the inverse variance method. A random-effects model was used, as it was assumed that the study effect sizes would not be identical due to the inherent heterogeneity among the studies. Statistical heterogeneity was assessed with the I 2 statistic, in which a I To compare the various routes of administering SCS, a mixed-treatment analysis was conducted using a Bayesian network model to compare relapse between all SCS routes simultaneously to placebo in a single analysis. The included studies were similar in populations, outcomes, and designs, and the clinical heterogeneity was judged by the research team to be sufficiently low. Logarithmic OR were modeled using noninformative prior distributions. Markov Chain Monte Carlo simulations using WinBUGS 12 software (MRC Biostatistics unit, Cambridge Institute of Public Health) Version 1.4 were carried out to obtain simultaneous estimates of all interventions compared with placebo, as well as estimates of which interventions were the best. 13 A burn-in sample of 220,000 iterations, in which the results of the first 20,000 iterations are ignored, was followed by 200,000 iterations used to compute estimates. Results are reported with 95% credibility intervals (CrI) using a random-effects model. The analyses were checked for consistency using cross validation of all contrasts that had direct evidence.
14 Probability of best (PB) was reported for comparisons between the interventions. The figures were produced using TIBCO S+ (Spotfire Technology Network), 8.2 Workbench. Relapse within 10 days or less or greater than 10 days was the only subgroup analysis considered.
RESULTS
Search Results
The systematic, Airways Group Specialised Register, and gray literature search identified 511, 1,217, and 141 articles, respectively (see Figure 1) . Fifty-one studies were selected as potentially relevant and accessed for full-text review. Thirty-eight studies were excluded after full-text review, while the remaining 13 were included in the review. One of the included studies 15 was translated into English by a research associate fluent in Spanish, who assisted with the study risk of bias assessment and data extraction. Table 1 for reports characteristics of included studies, which are summarized below.
Study Characteristics
Design
All of the studies were randomized controlled trials. Eleven of the included studies were published in peerreviewed journals, 10, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] while two of the studies were published abstracts. 25, 26 The relapse rates from one study was not included in the analysis due to a lack of information, which the authors were unable to clarify. 26 
Patients
The majority of studies were published in the United states, 10, [18] [19] [20] [22] [23] [24] 26 followed by Canada, 16, 17 Indonesia, 25 Mexico, 15 and Taiwan. 21 The severity of the asthma exacerbation in the included patients was not reported in the majority of studies. 10, [16] [17] [18] [20] [21] [22] 26 Some studies summarized it as mild-moderate, 19, 23, 24 moderate-severe, 25 and severe.
15
Interventions Prednisone and prednisolone were the most common PO corticosteroids provided [15] [16] [17] 19, [23] [24] [25] [26] followed by dexamethasone, 19, 21, 23, 26 methylprednisolone, 10, 18, 20 and deflazacort. 15 Eight studies assessed a PO lc corticosteroid regimen 10, [15] [16] [17] [18] 20, 24, 25 while four studies utilized a PO sc corticosteroid regimen, with each study providing 5 days of PO prednisone treatment. 19, 23, 24, 26 No studies comparing PO sc versus PO lc corticosteroids could be identified.
A total of six studies examined the efficacy of a single dose of IM corticosteroids prior to discharge. The most common IM corticosteroid was methlyprednisolone, 18, 20, 22 followed by betamethasone, 16 dexamethasone, 21 and triamcinolone. 24 
Co-interventions
Common co-interventions provided in the ED included beta 2-agonists, 10 16, 19, 22, 24 Two studies reported to discontinuing patients previous medications prior to discharge. 10, 18 Four studies permitted the use of ICS after discharge. 16 and 28 25 days. Three studies assessed relapse at multiple time periods. 16, 20, 26 Additional information on relapse for one study 10 was retrieved from supplemental materials. 27 All studies collected relapse events via patient interviews, except one study, which utilized health records. 16 
Risk of Bias Assessment
Two of 12 studies was assessed as having high risk of bias, 22, 23 while the remaining studies had unclear risk of bias 10,15-26 (see Figure 2) . The majority of studies did not provide detailed information on randomization, allocation concealment, or blinding. Only two studies had a protocol available for review. 16, 23 Primary Outcome SCS Versus Placebo. Four studies involving 292 patients compared any SCS versus placebo to reduce relapse in adults within 21 days of discharge. Corticosteroids significantly reduced relapse compared to placebo (RR = 0.43; 95% CI = 0.25 to 0.74; p = 0.002; Figure 3 ). Statistical heterogeneity was low (I 2 = 0%). placebo. There was a 69.0% probability of IM corticosteroids being the most effective treatment, followed by PO sc (PB = 20.6%) and PO lc (PB = 10.2%) corticosteroids.
Relapse After 10 Days Post Discharge. The network analysis of the effects of SCS on relapse after 10 days postdischarge could not be completed as planned due to a limited number of available studies.
DISCUSSION
Despite the fact that most patients with acute asthma seen in EDs are safely discharged home, 28 many patients are at risk for relapse. While guidelines recommend the use of SCS, 29 the optimal route to prevent relapse is unclear. This review was designed to summarize the effectiveness of SCS to reduce relapse and explore the evidence for route and duration of SCS in adult patients discharged from the ED.
Using a comprehensive literature search and strategies to avoid publication and selection bias, 13 studies involving 1,284 patients were identified; the results of this review confirmed SCS to be more effective at preventing asthma relapse than placebo. In the network meta-analysis, IM corticosteroids were identified as the most effective route to reduce relapse within 10 days after discharge, followed by long-course SCS (e.g., prednisone). It is unclear whether noncompliance with PO medications was the reason why IM corticosteroids were found to be the most effective SCS route as only three studies reported assessing patient compliance with PO corticosteroids (reported at 67, 18 94, 24 and 95% 16 ). While both long-course and IM corticosteroids were shown to be superior to placebo, this network analysis showed that the latter was much more often the more effective of the two. Moreover, a significant reduction in relapse was found after treatment with long-course corticosteroids; however, PB analysis favored shortcourse over long-course PO corticosteroids due to the wider CIs. 30 It is likely that the dearth of studies reporting on the use of PO short-course corticosteroids in adults is the reason for the lack of precision. Of the studies reporting on relapse within 10 days postdischarge, only one study 24 utilized PO short-course corticosteroids. Additional studies assessing PO shortcourse corticosteroids in adults recommended. Unfortunately, due to a limited number of available studies, a network meta-analysis of relapse 10 days postdischarge could not be completed as planned. Additional research examining the long-term ability of SCS to reduce relapse is strongly recommended.
While IM corticosteroid medications are effective at reducing relapses, this is likely explained by the relative nonadherence of patients to complex and prolonged PO corticosteroid regimens. In general, given patient preference for PO agents, IM agents should be reserved for known noncompliant patients. Clinicians discharging patients with acute asthma should otherwise prescribe simplified regimens (once daily for at least 7 days), avoid tapering, and reinforce the need to complete the course.
LIMITATIONS
There are specific limitations associated with this review. First, this study only reported on relapse; data on quality of life, symptoms, beta 2-agonists use, pulmonary functions, and other outcomes were not the focus of this review. Second, the effects of co-interventions on relapse could not be examined, as it is impossible to determine their influence without completing an individual patient meta-analysis, which was outside the scope review. Third, this review did not examine dosing of SCS and its possible effect on relapse rates. Fourth, it is unknown whether publication bias limited the ability of this review to identify all completed trials.
CONCLUSIONS
This review reveals conclusive evidence for the benefit of systemic corticosteroids in reducing short-term relapse for adult patients with acute asthma discharged from an ED. A single dose of intramuscular corticosteroids was shown to be the most effective treatment option to reduce future relapse within 10 days postdischarge, followed by long-course oral corticosteroids. A paucity of data has limited any recommendations regarding the use of oral short-course corticosteroids in adults. More highquality studies comparing the effectiveness of intramuscular and short/long courses of oral corticosteroids are recommended. Overall, the results of this review suggest that oral long-course corticosteroids should be considered the preferred treatment option for most for adult patients with acute asthma discharged from the ED until additional comparative effectiveness trials emerge. Rodriguez for her assistance with translation for one of the included studies. Finally, we thank Elizabeth Stovold for providing the search results from the Airways Group Specialised Register.
